IL-33 can be released by necrotic cells following tissue damage as an endogenous danger signal or “alarmin” [45], binding to the ST2 protein (the only well-documented receptor for IL-33) to play a complex immunomodulatory role in rodent models of neurological diseases, such as AD, MS, and stroke [18, 38, 40]. This evidence concerns the gene IL33 and myeloid sarcoma.